Roche severs ties with 4D Molecular Therapeutics over blindness gene therapy, marking another setback for the field
Roche is turning its nose up over a gene therapy program targeting an inherited form of night blindness, signaling the latest setback for such treatments in eye-related diseases.
As the space continues to reel from Biogen’s major Phase III flop last week, Roche is handing back rights to a program from 4D Molecular Therapeutics, the biotech announced Thursday morning. The termination of the licensing agreement will be effective as of Sept. 16, 4DMT said.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.